Advanced Enzyme Technologies Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The management did not discuss plans for acquisitions or major financing activities in the near term. - Mukund Kabra mentioned that decisions like buybacks or dividends are taken by the Board, with dividend increases planned, but buyback is not considered efficient. - No comments were made about raising fresh equity or debt capital during the call. - The focus appears to be on organic growth, R&D expansion, and scaling up operations rather than fundraising. - Overall, there is no indication of any immediate or planned debt or equity fundraising from the management during this earnings call.

- Advanced Enzyme Technologies is expanding its R&D capabilities, aiming to increase R&D capacity by threefold. - A new R&D center is being built in Nasik, expected to be fully operational by the end of next year, facilitating gradual ramp-up in R&D activities. - Current R&D expenditure for 6 months was INR143 million (vs. INR121 million last year), with capex of INR18 million (up from INR5 million last year). - Investments are focused on hiring new scientists, expanding infrastructure, and acquiring new equipment, addressing space constraints limiting hiring. - The company is also investing in novel enzyme and biocatalyst development with a long-term strategic focus, though some details are kept confidential for IP reasons. - No immediate plans for acquisitions or buybacks were mentioned; acquisition in the US is not expected within the next year. - Freight cost issues due to geopolitical factors led to an impact of approx. INR1.5 crores in the quarter, indicating attention to logistics investments.

- The company expects single-digit revenue growth for the full financial year '25, revised down from earlier double-digit growth guidance. - Growth in India is expected to be muted or flat this year, largely due to delays in biocatalyst sales and competition in key product segments like serratiopeptidase. - The US business is seeing continuous upward momentum, with expectations of better performance in the second half, particularly from Evoxx and Nutraceutical segments. - Europe and other international markets are expected to show moderate improvements in the latter half of the year. - The business operates mainly on a purchase order basis, without long-term contracts, so visibility is limited; growth depends on ongoing customer trials and new product approvals. - Longer-term growth beyond FY '25 depends heavily on expanding R&D capabilities to develop more products and biocatalyst molecules. - Achieving consistent 25% growth is considered difficult without significant ramp-up in R&D and product pipeline expansion.

- Company expects single-digit revenue growth for the full financial year 2025, revised from earlier hopes of double-digit growth due to some deferred sales and market challenges. - EBITDA growth is typically 2x to 3x the revenue growth; however, with single-digit revenue growth, EBITDA growth is also expected to moderate accordingly. - EBITDA margin guidance is around 30% to 33% as revenue picks up in second half; Q2 margin was subdued at 29% due to lower top line and higher freight costs. - Profitability is expected to improve in second half, with the US business showing stronger growth prospects and some recovery expected from deferred sales. - EPS and PAT are expected to reflect the same moderation, with prior quarters showing a PAT margin around 22%-23%. - No near-term large acquisitions planned that might significantly impact earnings. - Long-term growth depends on R&D expansion and new product development to enhance scale and margins.

- The company operates primarily on a purchase order basis without long-term contracts. - The number of purchase orders (POs) at any given time is typically not more than INR 10-12 crores. - Customers often undergo trials and validations for new products, which can delay order finalization. - Orders expected from trials are sometimes deferred, possibly affecting growth timelines (e.g., some business expected in FY25 may shift to FY26). - Mukund Kabra mentioned the difficulty in providing exact orderbook numbers due to the nature of business. - The outlook and order expectations are based more on anticipated additions of new customers and their potential business rather than fixed long-term orders. - Some orders related to Evoxx have been received, with POs expected to pan out over the entire year. - Shipment and delivery delays (e.g., due to freight and logistics issues) have impacted the timing of order realization.